Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and licensing agreement with Takeda (TYO: 4502), a leading pharmaceutical company in Japan. The partnership aims to discover and develop novel molecular glue degraders targeting oncology, neuroscience, and inflammation.
According to the agreement, Degron Therapeutics will receive an upfront payment and is eligible for potential future preclinical, clinical development, and commercial milestone payments that could total USD 1.2 billion if all related milestones are achieved throughout the agreement’s duration. Additionally, Degron is eligible for tiered royalty payments on sales of any commercialized products resulting from the collaboration. The two parties have the option to expand the collaboration to include more targets. Takeda will also make an equity investment in Degron Therapeutics, which will retain full ownership of its pipeline programs.- Flcube.com
